BIO-MICRO: Biomarkers and Intervention Outcomes in Micronutrient Optimizationcore
BIO-MICRO · Horizon Europe grant · 2026-03-01–2030-02-28
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-MSCA-2024-DN-01 · scheme HORIZON-TMA-MSCA-DN · topic HORIZON-MSCA-2024-DN-01-01. CORDIS record →
Objective
European micronutrient (MN) guidelines explicitly recommend to replete any MN deficiency in critically ill patients. MNs are crucial for immune defence, cellular metabolism and as antioxidant. Critically ill patients have increased requirements for MNs which can result in severe deficiencies and worse clinical outcomes. There are currently no accurate methods to diagnose MN deficiencies in critically ill patients. MN plasma concentrations are substantially affected by inflammation. MN concentrations in erythrocytes and leukocytes or new functional markers may better reflect real deficiencies. Furthermore, most intervention trials with high-dose MN monotherapy yielded mixed results on clinical outcomes. Due to the absence of accurate monitoring tools of MN body status, all patients received fixed high-dose MN monotherapy. Personalized MN therapy based on subphenotyping of patients and accurate estimation of individual metabolic demands in all phases of disease may yield better outcome than this one-size-fits-all strategy. In addition, more insight in the complex interplay between MNs and the role of MNs in post-ICU phase is necessary to guide future trials. BIO-MICRO consists of physicians, biologists, methodologists, trialists, health scientists, clinical chemists, patient representatives and industrial participants and aims to train innovative research fellows with interdisciplinary and intersectoral skills to develop the urgently needed strategies for MN personalized therapy in critically ill patients. They will develop new analytics for reliably determination MN body status, investigate subphenotypes of patients likely to benefit from MN therapy, enable guidance with appropriate timing of MN therapy, investigate the interplay between MNs and explore the role of MNs in the rehabilitation phase. This will ultimately lead to significantly decreased mortality and organ dysfunctions, shorter ICU stay, improvement of quality of life and significant cost reductions.
Beneficiaries (14)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| STICHTING AMSTERDAM UMC | NL | coordinator | €610,572 | |
| RANDOX TEORANTA | IE | participant | €682,174 | |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | DE | participant | €580,545 | |
| UNIVERSITA DEGLI STUDI DI FOGGIA | IT | participant | €563,510 | |
| REINER HAGA MEDISCH DIAGNOSTISCH CENTRUM BV | NL | participant | €305,286 | |
| Stichting Martini Ziekenhuis | NL | participant | €305,286 | |
| STICHTING ZIEKENHUIS GELDERSE VALLEI | NL | participant | €305,286 | |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | DE | participant | €290,272 | |
| DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG POTSDAM REHBRUECKE | DE | participant | €290,272 | |
| Diagnotix BV | NL | associatedPartner | — | |
| UNIVERSITAET POTSDAM | DE | associatedPartner | — | |
| WAGENINGEN UNIVERSITY | NL | associatedPartner | — | |
| STICHTING VU | NL | associatedPartner | — | |
| DeWolfPact b.v. | NL | associatedPartner | — |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.